definiens: shall mean the aggregate of the following payments received by [COMPANY] from a subli censee of a [COMPANY] CDK Compound : ( i ) up - front cash or license fees ; ( ii ) proceeds received by Mit otix from the sale of securities of [COMPANY] at grea ter than fair market value that is in lieu of, or in additio n to, up - front cash or license fees ; ( iii ) mileston es paid to [COMPANY] ; ( iv ) royalty revenue received based on net sales of [COMPANY] CDK Product by the sublicensee ; ( v ) other consideration received for which the equivale nt fair cash value of such consideration can reason ably be determined by the parties, including but not lim ited to, rights in products or compounds ; and ( vi ) FTE funding above * * * Certain information on this page has been omitted a nd filed separately with the Securities and Exchang e Commission . Confidential treatment has been request ed with respect to the omitted portions